News & Updates
The latest developments in peptide research, regulation, clinical trials, and market trends. Updated daily by the Volta Peptides editorial team.
Wegovy News: Oral GLP-1 Tracker Shows Market Share Ceiling for Novo's Pill
Recent Wegovy news suggests Novo Nordisk's oral GLP-1 pill is struggling to break through a market share ceiling, according to industry reports. This analysis explores the implications for peptide researchers and the broader GLP-1 landscape.
Meant Launches LegitScript-Certified GLP-1 Telehealth Platform with Coaching
Meant has introduced a new telehealth platform for GLP-1 therapies that has earned LegitScript certification. The platform combines medical oversight with personalized coaching to support patients using GLP-1 medications. This launch marks a step forward in integrating digital health services with weight management treatments.
HumeCare Oral GLP-1 Review 2026: A Closer Look at the Option
A 2026 review of HumeCare's oral GLP-1 product examines whether it could serve as a convenient alternative to injectable options. The article highlights the growing interest in oral formulations and what HumeCare offers. It provides an overview of the product's potential role in the market.
PolyPeptide Group Stock Holds Below CHF 44 Despite Margin Gains
PolyPeptide Group (SWX:PPGN) shares continue to trade under the CHF 44 offer price despite recent margin momentum, according to a market analysis. The article examines the disconnect between the company's improving margins and its stock price performance. Investors are watching whether the gap between fundamentals and valuation will close.
5 Mental Health Benefits of GLP-1 Drugs Like Ozempic and Wegovy: Latest Ozempic News
Recent reports highlight five mental health benefits associated with GLP-1 drugs like Ozempic and Wegovy, extending beyond weight loss. This analysis covers the implications for peptide researchers and the broader industry.
Tesamorelin Research Interest Grows Among Synthetic GHRPs
Synthetic growth hormone-releasing peptides (GHRPs) are drawing increasing attention in scientific research, with tesamorelin emerging as a focal point. The compound, a synthetic analog of growth hormone-releasing hormone, is being studied for its potential to modulate growth hormone levels. This article examines the rising research interest in tesamorelin and its place within the broader class of synthetic GHRPs.
PolyPeptide Reports Strong H1 2026 Growth and Raises Full-Year Guidance
PolyPeptide Group delivered robust financial results for the first half of fiscal 2026, prompting management to lift its full-year outlook. The earnings call transcript, published on Investing.com, details the company's improved revenue and profitability metrics. Executives cited strong demand across its peptide CDMO services as a key driver.
Eli Lilly sues pharmacies over early retatrutide sales: retatrutide news
Eli Lilly is taking legal action against pharmacies and peptide vendors for selling retatrutide before approval. This retatrutide news highlights the growing tension between pharmaceutical IP protection and the peptide research market.
Eli Lilly targets black market for experimental weight-loss drug
Eli Lilly is taking action against the illicit market for its experimental weight-loss drug. The company is reportedly addressing unauthorized sales of the medication. This move comes as demand for weight-loss treatments continues to rise.
Arch Biopartners Expands LSALT Peptide Trial to US Sites
Arch Biopartners has announced plans to expand its clinical trial of the LSALT peptide into the United States. The move extends the company's research into the peptide's potential therapeutic applications. Details of the expansion were reported on August 12, 2026.
GLP-1 Users Cut Grocery Spending, Food Dive Reports
A Food Dive report indicates that people taking GLP-1 medications are reducing their grocery purchases. The article, published on August 12, 2026, highlights a notable decline in food spending among this group. This trend reflects changing consumption patterns linked to the use of these drugs.
Mounjaro News: GLP-1 Drug May Lower Heart Attack Risk in Type 2 Diabetes
Recent reports suggest that Mounjaro, a GLP-1 receptor agonist for type 2 diabetes, may lower heart attack risk. This analysis explores the news, its potential implications for peptide research, and what it means for the industry.
Ozempic Manufacturing News: Eli Lilly vs. Novo Nordisk and the New Competitive Moat
Recent reports suggest that manufacturing capacity has become a key battleground for Eli Lilly and Novo Nordisk in the GLP-1 space. This analysis explores how production scale and supply chain improvements may shape the competitive landscape for peptide-based therapies.
Ozempic News: New GLP-1 Pill Shows 12% Weight Loss in 36 Weeks
Recent ozempic news highlights a new oral GLP-1 drug that reportedly delivers up to 12% weight loss over 36 weeks. While the specific medication name remains unconfirmed, this development signals continued progress in GLP-1 research. Learn what this means for peptide researchers and industry professionals.
Semaglutide News: Orthopedic Surgeon Shares Key Insights on Ozempic and Wegovy
Recent semaglutide news highlights an orthopedic surgeon's perspective on Ozempic and Wegovy. The report touches on weight loss efficacy and safety considerations, offering context for researchers and industry professionals tracking GLP-1 developments.
Supercharged News: How Social Media Is Warping Teen Psyches in the GLP-1 Boom
A recent Bloomberg report highlights how the GLP-1 boom, supercharged by social media, is warping teen psyches. This analysis explores the implications for peptide research and the importance of responsible communication in the digital age.
Yale Study Could Reshape Understanding of GLP-1 Drugs
A new study from YaleNews, published August 10, 2026, may change how researchers and clinicians think about GLP-1 receptor agonists. The findings challenge existing assumptions about these widely used medications, potentially influencing future therapeutic approaches and research directions.
US Peptide Synthesis Reagents Market Analysis and Forecast
IndexBox has released a comprehensive market analysis for peptide synthesis reagents in the United States, covering size, trends, and forecasts. The report provides detailed insights into the industry's current state and future outlook. Key data points include market volume, value, and growth projections.
Ozempic News: GLP-1s May Lower Fracture Risk in Type 2 Diabetes
Recent reports suggest that GLP-1 receptor agonists like Ozempic and Mounjaro may reduce fracture risk in type 2 diabetes patients. While the findings are preliminary, they add to the growing evidence of benefits beyond glucose control. Researchers and industry professionals are watching closely.
Why Big Pharma Avoids Unapproved Peptide Investments
A recent report from the Australian Financial Review explores why major pharmaceutical companies have not committed funding to unapproved peptides. The article examines the regulatory, scientific, and commercial barriers that keep big pharma on the sidelines. It highlights the cautious approach of the industry toward these compounds.
GLP-1 Stock Showdown: Eli Lilly vs. Viking Therapeutics
Investors weighing GLP-1 exposure often compare Eli Lilly and Viking Therapeutics. This analysis reviews both companies' positions in the weight-loss drug market, highlighting key differences in pipeline maturity, clinical data, and market valuation. The article presents the facts to help readers decide which stock might be the better buy.
Eli Lilly Sets FDA Filing Date for Next Weight-Loss Drug, Pressuring Novo Nordisk
Eli Lilly has officially announced the timing of its FDA filing for its next weight-loss drug, a move that intensifies competitive pressure on Novo Nordisk. The announcement clarifies the regulatory timeline for the highly anticipated treatment.
Eli Lilly Sets Retatrutide FDA Filing Date; Stock Target Questioned
Eli Lilly has locked in a U.S. Food and Drug Administration (FDA) filing date for its investigational obesity drug retatrutide, according to a recent report. The news has sparked analyst discussion about whether the company's stock could reach $1,750 by 2027. The filing date marks a key regulatory milestone for the potential blockbuster therapy.
CVS Health Expands GLP-1 Access With $29 Visits, Lilly Deal
CVS Health is broadening patient access to GLP-1 medications through $29 virtual visits and a new partnership with Eli Lilly. The initiative aims to simplify prescribing and lower cost barriers for weight-management drugs. Details of the collaboration and visit pricing were announced in a recent Pharmacy Times report.
Showing 24 of 288 articles